Skip to main content

Table 3 Adverse events (G1-2 and G3-4) for ACTH vs TCH

From: Cost-effectiveness of paclitaxel, doxorubicin, cyclophosphamide and trastuzumab versus docetaxel, cisplatin and trastuzumab in new adjuvant therapy of breast cancer in china

 

ACTH Adverse events

TCH Adverse events

G1-2

G3-4

G1-2

G3-4

Anemia

5 (20%)

4(16%)

4(25%)

7(44%)

Infection

3 (12%)

18(72%)

0

5(31.25%)

Neutropenia

5 (20%)

7(28%)

2(12.5%)

1(6%)

Hepatotoxicity

2 (8%)

10(40%)

1(6%)

4(25%)

Renal toxicity

2 (8%)

0

2(12.5%)

0

Cardiac toxicity

 Symptomatic dysfunction

8 (32%)

0

3(18.75%)

0

 Cardiac failure

0

0

0

0